Durability Of Initial Platelet Count Response In Patients Treated With Avatrombopag For Immune Thrombocytopenia (Itp): Post-Hoc Results From A Phase 3 Clinical Study

Background: The clinical management of ITP has been evolving. Thrombopoietin receptor agonists (TPO-RAs) have become widely utilized as subsequent treatments, and the 2019 ASH guidelines recommend their use over rituximab to achieve a durable response.